000			05720cam a2200421Mi 4500
001			94909
003			ES-MaUEC
005			20230102112637.0
006			m o d
007			cr |n|||||||||
008			161125s2017 sz o 001 0 eng d
020			_a3319408542 _q(electronic bk.)
020			_a9783319408545 _q(electronic bk.)
020			_z3319408526 _q(print)
020			_z9783319408521 _q(print)
035			_a(OCoLC)964326878 _z(OCoLC)970781404 _z(OCoLC)971030601 _z(OCoLC)974649896 _z(OCoLC)1000116091 _z(OCoLC)1005772306
040			_aYDX _cYDX _dN$T _dIDEBK _dEBLCP _dGW5XE _dOCLCF _dN$T _dAZU _dUAB _dCOO _dOCLCQ _dUPM _dIOG _dMERER _dESU _dOCLCQ _dJBG _dIAD _dICW _dICN _dOTZ _dOCLCQ _dVT2 _dU3W _dES-MaUEC _bspa
050		4	_aRM847 _b2017 EB
245	0	0	_aIncreasing the therapeutic ratio of radiotherapy _cPhilip J. Tofilon, Kevin Camphausen, editors.
264		1	_aCham, Switzerland _bHumana Press _c2017
300			_a1 recurso en línea
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	0		_aCancer drug discovery and development _x2196-9906
505	0		_aContributors; Chapter 1: Improving the€Therapeutic Ratio of€Radiotherapy by Targeting the€DNA Damage Response; Introduction; The DNA Damage Response (DDR); Detection of€Radiation-Induced DNA Damage and€Initiation of€DDR; Ataxia Telangiectasia Mutated (ATM); Ataxia Telangiectasia and€Rad 3 Related (ATR); DNA-Dependent Protein Kinase (DNA-PK); Cell Cycle Checkpoint Control; DNA Repair Processes; Non-homologous End Joining (NHEJ); Homologous Recombination (HR); Poly (ADP-Ribose) Polymerases (PARPs); DNA Damage Response as€a€Therapeutic Target; PARP Inhibition.
505	8		_aATM Inhibition ATR Inhibition; Chk1 Inhibition; Inhibition of€NHEJ; Rad51 Inhibition; Combination DDR Inhibition; DDR Kinase Inhibition and€Cancer Stem Cell Theory; Combining Radiotherapy and€DDR Kinase Inhibition in€the€Clinic; Clinical Trials of€DDR Kinase Inhibition; Biomarkers; Conclusion; References; Chapter 2: Receptor Tyrosine Kinases as€Targets for€Enhancing Tumor Radiosensitivity; Introduction; EGFR; VEGF/VEGFR; c-Met; Other RTKs; Conclusion; References; Chapter 3: Histone Deacetylase Inhibitors and€Tumor Radiosensitization; Introduction.
505	8		_aHistone Acetylation and Deacetylation Histone Acetylation and€Metabolism; Inhibitors of€Histone Deacetylation; HDAC Inhibitors and€Radiosensitization; In Vitro Radiosensitization; In Vivo Radiosensitization; Tumor Versus Normal Cells; Clinical Application of€HDAC Inhibitors and€Radiotherapy; Conclusion; References; Chapter 4: Radioprotection as€a€Method to€Enhance the€Therapeutic Ratio of€Radiotherapy; Background; Methods to€Improve the€Therapeutic Index of€Radiotherapy; Radioprotectors; Amifostine; Nitroxides; Other Candidate Radioprotectors; Radiation Mitigators.
505	8		_aTotal Body Exposures Dermatitis; Fibrosis; Central Nervous System Injury; Treatment; Challenges; References; Chapter 5: Application of€Functional Molecular Imaging in€Radiation Oncology; Introduction; Principles of€Established and€Emerging Advanced Molecular Imaging Technology; CT Imaging; Radionuclide Imaging; PET and€SPECT; MRI; Imaging of€Tumor Metabolism; 18F-FDG PET/CT; Hyperpolarized Metabolic MR; Imaging Cellular Proliferation; MRSI; Imaging Tumor Microenvironment; Methods for€Evaluating Hypoxia; DCE-MRI; BOLD-MRI; EPRI and€OMRI; Conclusion; Future Perspective.
520	3		_aCurrent cancer therapies are focused on three general strategies: modifying intrinsic radiosensitivity via molecular targeting, manipulating microenvironmental factors to enhance tumor susceptibility to radiation, and improving delivery of radiation to critical tumor locations while sparing normal tissues. The goal of this volume is to describe a number of promising approaches corresponding to each strategy. In general, research in radiation oncology tends to be siloed into fundamental biology, physics or treatment delivery. The strategies for improving therapeutic ratio encompassed in this book will involve each of these components of radiation oncology. Thus, they will illustrate the variety of disparate approaches available for potentially improving the efficacy of radiotherapy, which may then stimulate discussion across disciplines and foster further translational investigations. Although a goal of each chapter will be to highlight advances within an approach, of equal importance will be the delineation of barriers to successful clinical application and how to overcome or minimize such impediments. Along these lines, because therapeutic ratio incorporates both tumor and normal tissue radio response, a point of emphasis will be the mechanistic rationale for selectively modifying tumor (sensitization) or normal cells (protection). Finally, whereas the literature is replete with studies describing potential targets/strategies for increasing the therapeutic ratio for radiotherapy, this book will focus on those supported by in vivo data consistent with impending translational application along with those that are already being evaluated in the clinic.
650		7	_aRadioterapia _2embne _0(OCoLC)fst01088351 _0 _9139979
700	1		_aCamphausen, Kevin, _eeditor literario
700	1		_aTofilon, Philip J., _eeditor literario
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-40854-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aSpringer_Medicine_2017
998			_b02/2018 _dz _e- _zSI
999			_c94909 _d94909 _x1